跳至主要內容

藥品參考

Dostarlimab

Dostarlimab is a medicine in the class oncology. It is used for cancer.

最後更新 來源: US FDA label

僅供醫療專業人員參考。本頁為簡要摘要,並非醫療建議,亦不能取代官方仿單或臨床判斷。開立處方或調劑前請務必核實。

本頁的臨床內容僅提供英文版。

重點資訊

藥物類別
Oncology
ATC 代碼
L01FF07
常見劑型
注射劑
常見規格
50 mg/ml
已知交互作用
3 (中度: 2 · 輕微: 1)
商品名
2
國家與市場
2

劑型、規格與商品名稱會因國家而異。請核對您手上的產品。

用途

作用方式

Dostarlimab-gxly is a humanized IgG4 monoclonal antibody that binds the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.

成人常用劑量(仿單摘要)

Primary advanced or recurrent endometrial cancer: 500 mg IV every 3 weeks for 6 cycles with carboplatin and paclitaxel, then 1,000 mg monotherapy every 6 weeks thereafter; until disease progression, unacceptable toxicity, or up to 3 years

僅摘錄仿單中第一行劑量說明;完整的劑量內容請見 App。

懷孕與哺乳

懷孕
Unsafe Can cause fetal harm: PD-1 blockade can disrupt immune tolerance to the fetus and raise the risk of pregnancy loss; IgG4 crosses the placenta. Check pregnancy status; use effective contraception during treatment and for 4 months after the last dose.
哺乳
Unsafe No data on milk levels. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 4 months after the last dose.

已通報的副作用

  • Fatigue/asthenia
  • Anemia
  • Diarrhea
  • Nausea
  • Peripheral neuropathy (with carboplatin/paclitaxel)
  • Alopecia (with carboplatin/paclitaxel)

哪些人需要特別留意

  • Severe and fatal immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, transplant rejection) can occur in any organ; monitor liver enzymes, creatinine and thyroid function at baseline and periodically.
  • Infusion-related reactions: interrupt, slow the infusion, or permanently discontinue based on severity.
  • Fatal and other serious complications can occur in patients who receive allogeneic HSCT before or after PD-1/PD-L1 blocking antibody.

請告知藥師或醫師您是否懷孕或哺乳、是否患有腎臟或肝臟疾病、是否有過敏,以及您正在使用的所有其他藥物或保健品。

重要交互作用 (3)

Pro+ 會員專屬

解鎖完整頁面

建立帳號並開始 Pro+ 試用,即可開啟 Dostarlimab 的完整藥品專論:劑量、懷孕與哺乳、副作用、警示及所有交互作用。

  • Dosing by age, kidney and liver function, and further dose lines
  • Renal and hepatic dose adjustments
  • Dosing in older adults
  • How to give it
  • Pharmacokinetics
  • Patient counselling points
  • IV preparation and dilution

在網頁版免費試用 Pro+ 7 天,無需信用卡。

同類別的其他藥品

常見問題

What is Dostarlimab used for?

Dostarlimab is a medicine in the class oncology. It is used for Cancer, Endometrial carcinoma.

What side effects have been reported with Dostarlimab?

Fatigue/asthenia, Anemia, Diarrhea, Nausea, Peripheral neuropathy (with carboplatin/paclitaxel), Alopecia (with carboplatin/paclitaxel).

Can Dostarlimab be taken in pregnancy or while breastfeeding?

Pregnancy: Unsafe. Can cause fetal harm: PD-1 blockade can disrupt immune tolerance to the fetus and raise the risk of pregnancy loss; IgG4 crosses the placenta. Check pregnancy status; use effective contraception during treatment and for 4 months after the last dose. Breastfeeding: Unsafe. No data on milk levels. Because of possible serious reactions in the infant, do not breastfeed during treatment and for 4 months after the last dose.

What does Dostarlimab interact with?

MediHelp lists 3 known interactions for Dostarlimab. Moderate: 2 · Minor: 1. The most serious include Piperacillin, Piperacillin-tazobactam, Penicillin g.

在 MediHelp App 中取得完整藥品專論、劑量資訊與交互作用檢查

在 MediHelp App 中開啟完整參考資料、檢查多種藥物間的交互作用,並使用劑量工具。

依 A–Z 瀏覽 · 藥品參考

取得 App 登入